PM
TPTX

Prosight Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Prosight Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,602
Closed -$1.65M – 63
2020
Q2 		$1.65M Buy
+25,602
New +$1.48M 0.71% 33

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Prosight Management's TPTX Position: Q3 2020 in Review

Prosight Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2020, closing a stake of 25,602 shares — an estimated $1.65M sold.

Prosight Management first reported a position in TPTX in Q2 2020 and held it in 1 quarter. The position peaked at $1.65M in Q2 2020. 166 funds tracked by Wall St. Rank hold TPTX as of Q3 2020.

  • Prosight Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Prosight Management sold 25,602 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $1.65M.
  • Prosight Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Prosight Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.65M in Q2 2020.
  • 166 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Prosight Management's 13F filing for Q3 2020, filed 13 Nov 2020.